The
canalicular multispecific organic anion transporter (
cMOAT), also termed MRP2, is a recently identified
ATP-binding cassette transporter. We previously established stable human
cMOAT cDNA-transfected cells, LLC/
cMOAT-1 from LLC-PK1 cells, and LLC/CMV cells that were transfected with an empty vector. We found that LLC/
cMOAT-1 cells have increased resistance to
vincristine (VCR), 7-ethyl-10-hydroxy-camptothecin, and
cisplatin but not to
etoposide. The multidrug resistance-reversing agents
cyclosporin A (CsA) and 2-[4-(diphenylmethyl)-1-piperazinyl]-5-(trans-4,6-dimethyl-1,3, 2-dioxaphosphorinan-2-yl)-2, 6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate P-
oxide (PAK-104P) almost completely reversed the resistance to VCR, 7-ethyl-10-hydroxy-camptothecin, and
cisplatin of LLC/
cMOAT-1 cells; and DL-
buthionine-(S,R)-sulfoximine, (3'-oxo-4-butenyl-4-methyl-
threonine(1), (
valine(2))
cyclosporin (
PSC833), and 3-([(3-(2-[7-chloro-2-quinolinyl]ethenyl)phenyl)-((3-dimethylamino-3- oxopropyl)-thio)-methyl]thio)
propanoic acid (MK571) partially reversed the resistance to these drugs. CsA and
PAK-104P at 10 microM enhanced the accumulation of VCR in LLC/
cMOAT-1 cells almost to the level in LLC/CMV cells without the agents. The efflux of VCR from LLC/
cMOAT-1 cells was enhanced compared with LLC/CMV cells and inhibited by CsA and
PAK-104P. Transport of
leukotriene C(4) (LTC(4)) and S-(2, 4-dinitrophenyl)
glutathione also was studied with membrane vesicles prepared from these cells. LTC(4) and S-(2, 4-dinitrophenyl)
glutathione were actively transported into membrane vesicles prepared from LLC/
cMOAT-1 cells. The K(m) and V(max) values for the uptake of LTC(4) by the LLC/
cMOAT-1 membrane vesicles were 0. 26 +/- 0.05 microM and 7.48 +/- 0.67 pmol/min/mg
protein, respectively. LTC(4) transport was competitively inhibited by
PAK-104P, CsA, MK571, and
PSC833, with K(i) values of 3.7, 4.7, 13.1, and 28.9 microM, respectively. These findings demonstrate that
cMOAT confers a novel drug-resistance phenotype. CsA and
PAK-104P may be useful for reversing
cMOAT-mediated drug resistance in
tumors.